These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


143 related items for PubMed ID: 1829879

  • 1. Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment of presumed bacteremia in febrile granulocytopenic patients.
    Nováková I, Donnelly JP, De Pauw B.
    Antimicrob Agents Chemother; 1991 Apr; 35(4):672-8. PubMed ID: 1829879
    [Abstract] [Full Text] [Related]

  • 2. Prospective randomized clinical trial of teicoplanin for empiric combined antibiotic therapy in febrile, granulocytopenic acute leukemia patients.
    Del Favero A, Menichetti F, Guerciolini R, Bucaneve G, Baldelli F, Aversa F, Terenzi A, Davis S, Pauluzzi S.
    Antimicrob Agents Chemother; 1987 Jul; 31(7):1126-9. PubMed ID: 2959198
    [Abstract] [Full Text] [Related]

  • 3. Teicoplanin as modification of initial empirical therapy in febrile granulocytopenic patients.
    Nováková IR, Donnelly JP, Verhagen CS, De Pauw BE.
    J Antimicrob Chemother; 1990 Jun; 25(6):985-93. PubMed ID: 2142486
    [Abstract] [Full Text] [Related]

  • 4. Options and limitations of teicoplanin in febrile granulocytopenic patients.
    De Pauw BE, Novakova IR, Donnelly JP.
    Br J Haematol; 1990 Dec; 76 Suppl 2():1-5. PubMed ID: 2149042
    [Abstract] [Full Text] [Related]

  • 5. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program.
    Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R, Del Favero A, Bucaneve G, Crokaert F, Kern WV, Klastersky J, Langenaeken I, Micozzi A, Padmos A, Paesmans M, Viscoli C, Glauser MP.
    Antimicrob Agents Chemother; 1996 May; 40(5):1108-15. PubMed ID: 8723449
    [Abstract] [Full Text] [Related]

  • 6. Using teicoplanin for empiric therapy of febrile neutropenic patients with haematological malignancies.
    Menichetti F, Del Favero A, Bucaneve G, Aversa F, Fiorio M.
    Br J Haematol; 1990 Dec; 76 Suppl 2():45-8. PubMed ID: 2149052
    [Abstract] [Full Text] [Related]

  • 7. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, Langenaeken J, Paesmans M, Viscoli C, Glauser MP.
    Antimicrob Agents Chemother; 1995 Feb; 39(2):445-52. PubMed ID: 7726513
    [Abstract] [Full Text] [Related]

  • 8. Ceftazidime plus teicoplanin versus ceftazidime plus amikacin as empiric therapy for fever in cancer patients with granulocytopenia.
    Meunier F, Van der Auwera P, Aoun M, Bron D.
    Br J Haematol; 1990 Dec; 76 Suppl 2():49-53. PubMed ID: 2149053
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Amikacin plus piperacillin versus ceftazidime as initial therapy in granulocytopenic patients with presumed bacteremia.
    Nováková I, Donnelly P, De Pauw B.
    Scand J Infect Dis; 1990 Dec; 22(6):705-11. PubMed ID: 2284577
    [Abstract] [Full Text] [Related]

  • 11. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program.
    Menichetti F, Martino P, Bucaneve G, Gentile G, D'Antonio D, Liso V, Ricci P, Nosari AM, Buelli M, Carotenuto M.
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2041-6. PubMed ID: 7811016
    [Abstract] [Full Text] [Related]

  • 12. A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients.
    de Pauw B, Williams K, de Neeff J, Bothof T, de Witte T, Holdrinet R, Haanen C.
    Antimicrob Agents Chemother; 1985 Dec; 28(6):824-8. PubMed ID: 3909956
    [Abstract] [Full Text] [Related]

  • 13. Ceftazidime and amikacin as empiric antibiotic therapy of febrile granulocytopenic patients with hematological malignancies. Report of 171 consecutive episodes.
    Todeschini G, Veneri D, Carlini S, Pizzolo G, Ambrosetti A, Bonesi R, Cassibba V, Vinante F, Meneghini V, Perona G.
    Hematol Oncol; 1991 Dec; 9(3):137-46. PubMed ID: 1937406
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A prospective study comparing vancomycin and teicoplanin as second-line empiric therapy for infection in neutropenic patients.
    Cony-Makhoul P, Brossard G, Marit G, Pellegrin JL, Texier-Maugein J, Reiffers J.
    Br J Haematol; 1990 Dec; 76 Suppl 2():35-40. PubMed ID: 2149050
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Ceftazidime with or without amikacin for the empiric treatment of localized infections in febrile, granulocytopenic patients.
    Nováková IR, Donnelly JP, de Pauw BE.
    Ann Hematol; 1991 Oct; 63(4):195-200. PubMed ID: 1932297
    [Abstract] [Full Text] [Related]

  • 19. Double beta-lactam regimen compared to an aminoglycoside/beta-lactam regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.
    Joshi JH, Newman KA, Brown BW, Finley RS, Ruxer RL, Moody MA, Schimpff SC.
    Support Care Cancer; 1993 Jul; 1(4):186-94. PubMed ID: 8193880
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 8.